 TAIPEI, Taiwan, July 05, 2021 GLOBE NEWSWIRE -- Taiwan Liposome Company Nasdaq: TLC, TWO: 4152, the company, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the companys board-approved stock swap transactions with Woods Investment Company, Ltd. Woods at a press conference held at 4:00pm Taipei time at the Taipei Exchange TPEx. Details of the stock swap transactions are as follows: 